{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:19:07Z","timestamp":1792081147955,"version":"4.4.0"},"reference-count":57,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.1210\/jc.2017-00448","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T15:07:54Z","timestamp":1494342474000},"page":"2770-2780","source":"Crossref","is-referenced-by-count":253,"title":["Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms"],"prefix":"10.1210","volume":"102","author":[{"given":"Danae A","family":"Delivanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Bornschlegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele M","family":"Merten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kottschade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Withers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan B","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"issue":"8","key":"key\n\t\t\t\t20170807140110_B1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170807140110_B2"},{"issue":"9948","key":"key\n\t\t\t\t20170807140110_B3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","year":"2014","journal-title":"Lancet"},{"issue":"26","key":"key\n\t\t\t\t20170807140110_B4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"KEYNOTE-006 investigators","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"key\n\t\t\t\t20170807140110_B5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"key\n\t\t\t\t20170807140110_B6","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"key\n\t\t\t\t20170807140110_B7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"key\n\t\t\t\t20170807140110_B8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10027","key":"key\n\t\t\t\t20170807140110_B9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"key\n\t\t\t\t20170807140110_B10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"key\n\t\t\t\t20170807140110_B11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"key\n\t\t\t\t20170807140110_B12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"key\n\t\t\t\t20170807140110_B13","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"key\n\t\t\t\t20170807140110_B14","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"key\n\t\t\t\t20170807140110_B15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"CheckMate 025 Investigators","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"key\n\t\t\t\t20170807140110_B16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"key\n\t\t\t\t20170807140110_B17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"key\n\t\t\t\t20170807140110_B18","first-page":"583","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small cell lung cancer","volume":"28","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170807140110_B19","first-page":"614","article-title":"2016 Thyroid abnormalities following the use of CTLA-4 and PD-1 inhibitors in the treatment of melanoma","volume":"86","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"key\n\t\t\t\t20170807140110_B20","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"key\n\t\t\t\t20170807140110_B21","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer","volume":"101","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170807140110_B22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"key\n\t\t\t\t20170807140110_B23","doi-asserted-by":"crossref","first-page":"e0121546","DOI":"10.1371\/journal.pone.0121546","article-title":"A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans","volume":"10","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"key\n\t\t\t\t20170807140110_B24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1210\/jcem-53-1-113","article-title":"Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves\u2019 disease and destruction-induced thyrotoxicosis","volume":"53","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key\n\t\t\t\t20170807140110_B25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1507\/endocrj.52.537","article-title":"Ratio of serum free triiodothyronine to free thyroxine in Graves\u2019 hyperthyroidism and thyrotoxicosis caused by painless thyroiditis","volume":"52","year":"2005","journal-title":"Endocr J"},{"issue":"2","key":"key\n\t\t\t\t20170807140110_B26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"key\n\t\t\t\t20170807140110_B27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/2326-6066.CIR-13-0094","article-title":"Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity","volume":"2","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"key\n\t\t\t\t20170807140110_B28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity","volume":"35","year":"2014","journal-title":"Endocr Rev"},{"issue":"11","key":"key\n\t\t\t\t20170807140110_B29","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","year":"1992","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20170807140110_B30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"19","key":"key\n\t\t\t\t20170807140110_B31","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"key\n\t\t\t\t20170807140110_B32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"5238","key":"key\n\t\t\t\t20170807140110_B33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","year":"1995","journal-title":"Science"},{"issue":"5","key":"key\n\t\t\t\t20170807140110_B34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","year":"1995","journal-title":"Immunity"},{"issue":"2","key":"key\n\t\t\t\t20170807140110_B35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","year":"1999","journal-title":"Immunity"},{"issue":"1","key":"key\n\t\t\t\t20170807140110_B36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"2","key":"key\n\t\t\t\t20170807140110_B37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"key\n\t\t\t\t20170807140110_B38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","year":"2016","journal-title":"Pituitary"},{"issue":"5","key":"key\n\t\t\t\t20170807140110_B39","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"key\n\t\t\t\t20170807140110_B40","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"issue":"230","key":"key\n\t\t\t\t20170807140110_B41","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20170807140110_B42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"5","key":"key\n\t\t\t\t20170807140110_B43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"key\n\t\t\t\t20170807140110_B44","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","year":"2012","journal-title":"OncoImmunology"},{"issue":"6","key":"key\n\t\t\t\t20170807140110_B45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","year":"2010","journal-title":"Nat Immunol"},{"issue":"5","key":"key\n\t\t\t\t20170807140110_B46","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/db07-0299","article-title":"Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes","volume":"57","year":"2008","journal-title":"Diabetes"},{"issue":"37","key":"key\n\t\t\t\t20170807140110_B47","doi-asserted-by":"crossref","first-page":"14034","DOI":"10.1073\/pnas.0806584105","article-title":"Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice","volume":"105","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"key\n\t\t\t\t20170807140110_B48","doi-asserted-by":"crossref","first-page":"e0154394","DOI":"10.1371\/journal.pone.0154394","article-title":"Association of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) Gene polymorphisms with autoimmune thyroid disease in children and adults: case-control study","volume":"11","year":"2016","journal-title":"PLoS One"},{"issue":"1-2","key":"key\n\t\t\t\t20170807140110_B49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2007.11.010","article-title":"The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology","volume":"30","year":"2008","journal-title":"J Autoimmun"},{"issue":"7","key":"key\n\t\t\t\t20170807140110_B50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.2010.1644","article-title":"Genetic susceptibility to autoimmune thyroid disease: past, present, and future","volume":"20","year":"2010","journal-title":"Thyroid"},{"issue":"4","key":"key\n\t\t\t\t20170807140110_B51","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4103\/2230-8210.137524","article-title":"Immunoregulatory T cells, LFA-3 and HLA-DR in autoimmune thyroid diseases","volume":"18","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"issue":"10","key":"key\n\t\t\t\t20170807140110_B52","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1172\/JCI28993.","article-title":"Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid","volume":"116","year":"2006","journal-title":"J Clin Invest"},{"issue":"12","key":"key\n\t\t\t\t20170807140110_B53","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tem.2014.09.001","article-title":"Hashimoto\u2019s thyroiditis and papillary thyroid cancer: are they immunologically linked?","volume":"25","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"key\n\t\t\t\t20170807140110_B54","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/er.2006-0044","article-title":"Role of chemokines in endocrine autoimmune diseases","volume":"28","year":"2007","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t20170807140110_B55","first-page":"147","article-title":"Cancer vaccines in the world of immune suppressive monocytes (CD14(+)HLA-DR(lo\/neg) cells): the gateway to improved responses","volume":"5","year":"2014","journal-title":"Front Immunol"},{"issue":"6","key":"key\n\t\t\t\t20170807140110_B56","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.106.039024","article-title":"Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland","volume":"48","year":"2007","journal-title":"J Nucl Med"},{"issue":"2","key":"key\n\t\t\t\t20170807140110_B57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00006231-200402000-00004","article-title":"Elevated 18F-FDG uptake in skeletal muscles and thymus: a clue for the diagnosis of Graves\u2019 disease","volume":"25","year":"2004","journal-title":"Nucl Med Commun"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/8\/2770\/19452759\/jc.2017-00448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T22:19:29Z","timestamp":1569277169000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jcem\/article\/102\/8\/2770\/3805504\/PembrolizumabInduced-Thyroiditis-Comprehensive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,5,9]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-00448","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,9]]}}}